MARKHAM, Ontario, July 12, 2019 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the second quarter of 2019, after market close on Wednesday, August 14, 2019. A conference call hosted by Michael Guerriere, President and Chief Executive Officer, and David B

CARLSBAD, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the Regatta® Lateral System, featuring NanoMetalene®

SAN JOSE, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Evolve Treatment Centers for Teens is excited to announce the grand opening of a new Partial Hospitalization Program (PHP) and Intensive Outpatient (IOP) treatment center in San Jose. Located at 1991 Park Avenue, the new day and evening treatment programs will serve teens struggling with mental health, substance

MARKHAM, Ontario, July 10, 2019 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) announced that it will report its 2019 second quarter results after market close on Wednesday, August 14, 2019. Lois Cormack, President and Chief Executive Officer, and Nitin Jain, Chief Financial Officer and C

SALT LAKE CITY and BOISE, Idaho , July 09, 2019 (GLOBE NEWSWIRE) -- NuMe TMS Clinics, a mental health clinic dedicated to providing the communities they serve with safe, effective depression treatment t

STOCKHOLM, July 11, 2019 /PRNewswire/ -- RaySearch has received 510(k) clearance from the FDA in the USA for version 8B of the treatment planning system RayStation®. RayStation 8B was released in December 2018 and includes the first machine le

UPPSALA, Sweden, July 11, 2019 /PRNewswire/ -- Q2 2019 highlightsTotal net revenues of SEK 201.2 million (199.7), up 0.8 percent and 19.1 percent when excluding ex-US milestone payment of SEK 30.8 million in Q2 2018 Zubsolv® US net revenues of

STOCKHOLM, July 11, 2019 /PRNewswire/ -- Significant events April-JuneJanssen presented data from the clinical Phase I study with ADC-1013 indicates good safety and shows initial signs of clinical effect. Study design and progress for the ongoing ATOR-1015 Phase I study showcased at ASCO. Clinical trial

STOCKHOLM, July 11, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the Alzheimer's Association International Conference® 2019 (AAIC®) to be held July 14-18 in Los Angeles, USA.

STOCKHOLM, July 11, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the Alzheimer's Association International Conference® 2019 (AAIC®) to be held July 14-18 in Los Angeles, USA.